Acceleron Pharma (XLRN) Tops Q2 EPS by 1c

Acceleron Pharma (NASDAQ: XLRN) reported Q2 EPS of ($0.63), $0.01 better than the analyst estimate of ($0.64). Revenue for the quarter came in at $3.7 million versus the consensus estimate of $3.8 million.

– MEDALIST and BELIEVE Phase 3 trials met all primary and key secondary endpoints –

– ACE-083 Part 2 of the Phase 2 trials in facioscapulohumeral muscular dystrophy and Charcot-Marie-Tooth disease are underway –

– PULSAR Phase 2 trial initiated with sotatercept in pulmonary arterial hypertension –

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c